WDR20b Inhibitors
WDR20b inhibitors represent a category of chemical compounds designed to selectively interact with a protein known as WDR20b, which is part of the larger WD repeat protein family. These proteins are named for the presence of the WD repeat, a conserved sequence motif of approximately 40 amino acids often terminating in tryptophan-aspartic acid (W-D) dipeptide. The WD repeats facilitate the formation of a propeller-like structure that enables protein-protein interactions. The specific protein WDR20b plays a role in various cellular processes due to its ability to act as a scaffold or mediator for complex assembly and signal transduction. Inhibitors of WDR20b are chemicals that can bind to this protein, altering its natural function by inhibiting its normal activity. The design of these inhibitors requires a deep understanding of the protein's structure, the conformation of its WD repeats, and the key domains responsible for its interactions.
The development of WDR20b inhibitors involves intricate chemical synthesis and molecular engineering to ensure specificity and high affinity for the target protein. Researchers typically employ a combination of computational modeling and empirical structure-activity relationship studies to identify and optimize potential inhibitory compounds. The molecular interaction between a WDR20b inhibitor and the protein can be characterized by various biophysical techniques, such as X-ray crystallography, NMR spectroscopy, or surface plasmon resonance, which provide insights into the binding mode, affinity, and kinetic properties of the interaction. The chemical structure of WDR20b inhibitors is often complex, featuring rings and heteroatoms that enable precise interactions with the protein's active site or allosteric sites. These interactions can lead to conformational changes in the protein, which disrupt its normal function. By understanding the intricacies of the WDR20b protein and its role in cellular mechanisms, scientists can design more effective inhibitors that can modulate the protein's activity with high selectivity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. Given that WDR20b may be involved in a protein complex that is regulated by phosphorylation, staurosporine could inhibit kinases that phosphorylate WDR20b or its associated proteins, thereby reducing WDR20b activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. If WDR20b activity is coupled with PI3K/AKT signaling, inhibiting PI3K could indirectly reduce WDR20b-mediated processes by impairing necessary signaling events. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. If WDR20b is regulated by ERK signaling, PD98059 could lead to decreased WDR20b activity by inhibiting upstream kinases. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. Should WDR20b be modulated by stress-activated pathways such as the p38 MAPK pathway, inhibition by SB203580 could diminish WDR20b's functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR (mechanistic target of rapamycin), which could affect WDR20b if it is part of signaling networks that rely on mTOR activity for protein synthesis regulation or other cellular processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor. If WDR20b function is associated with PI3K signaling, inhibition by wortmannin could impede any PI3K-dependent WDR20b activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), part of the MAPK pathway. If WDR20b activity is modulated by JNK signaling, using SP600125 could indirectly reduce WDR20b function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2. If WDR20b is downstream of MEK signaling, U0126 could indirectly decrease WDR20b activity by preventing MEK-mediated phosphorylation events. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. If WDR20b function requires proteasome-mediated degradation of regulatory proteins, bortezomib could lead to an accumulation of such proteins and indirectly decrease WDR20b activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a peptide aldehyde that inhibits proteasomes. Similar to bortezomib, if WDR20b activity is modulated by proteasome-mediated processes, MG132 could lead to an indirect decrease in WDR20b function. | ||||||